<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188835</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1459</org_study_id>
    <nct_id>NCT03188835</nct_id>
  </id_info>
  <brief_title>Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)</brief_title>
  <acronym>GB7</acronym>
  <official_title>Brown Fat Energy Metabolism During Cold Exposure: Effects of Fructose- or Glucose-rich Diet in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activating brown and beige adipose tissue (herein described as BAT) has been recently&#xD;
      recognized as a potential means to increase energy expenditure and lower blood glucose,&#xD;
      however, BAT activity appears to be reduced with obesity, aging or Type 2 Diabetes (T2D). BAT&#xD;
      has the unique capability to burn large amounts of sugar and fat and effectively dissipate&#xD;
      this energy as heat due to the expression of uncoupling protein 1 (UCP1) which is controlled&#xD;
      by a thermogenic gene program of transcription factors, co-activators and protein kinases.&#xD;
      Thus, enhancing the thermogenic gene program may be beneficial for treating obesity and T2D.&#xD;
      Despite the importance of BAT in regulating metabolism our understanding of the factors which&#xD;
      suppress its metabolic activity with obesity, aging and T2D are largely unknown. Recently, it&#xD;
      was shown that peripheral serotonin, which is regulated by the tryptophan hydroxylase 1&#xD;
      (Tph1), is a negative regulator of BAT metabolic activity. In addition to serotonin, other&#xD;
      studies have indicated that pro-inflammatory stimuli may also inhibit BAT metabolic activity.&#xD;
      These data suggest that reduced activation of BAT may be due to increases in peripheral&#xD;
      serotonin and inflammation. Importantly, the gut microbiome has recently been recognized as&#xD;
      an important regulator of serotonin and inflammatory pathways suggesting the observed effects&#xD;
      of the microbiome on obesity, T2D may be mediated in part through reductions in BAT activity.&#xD;
&#xD;
      One mechanism by which the environment may impact BAT activity and the thermogenic gene&#xD;
      program over the last 3 decades involves changes in our food supply as result of changes in&#xD;
      agricultural production (chlorpyrifos, glyphosphate) and the addition of food additives&#xD;
      (fructose). These agents have been reported to alter inflammation, serotonin metabolism and&#xD;
      the gut microbiome indicating a potential bimodal (direct and indirect via the microbiome)&#xD;
      mechanism by which they may alter the thermogenic gene program and contribute to chronic&#xD;
      metabolic disease. Thus, our overarching hypothesis is that environmental agents and&#xD;
      additives related to food production may contribute to the reduced metabolic activity of BAT.&#xD;
      The objective is to identify and characterize how food production agents and additives reduce&#xD;
      the metabolic activity of BAT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will follow 3 metabolic studies (A, B and C), each lasting 7.5h which includes a&#xD;
      3h acute cold exposure.&#xD;
&#xD;
      These studies will be almost identical: same perfusion of tracers, same number of Positron&#xD;
      Emission Tomography (PET) acquisitions and same number of Magnetic Resonance Imaging (MRI)&#xD;
      associated with Magnetic Resonance Spectroscopy (MRS) acquisitions .&#xD;
&#xD;
      The difference will be in the diet ingested by the subjects two weeks before each metabolic&#xD;
      study: during protocol A, the subjects will follow an isocaloric diet; during protocol B, the&#xD;
      subjects will follow the same isocaloric diet supplemented with a daily beverage containing&#xD;
      +25% of energy intake from fructose; and during protocol C, the subjects will follow the same&#xD;
      isocaloric diet supplemented with a daily beverage containing +25% of energy intake from&#xD;
      glucose.&#xD;
&#xD;
      Stool samples will be collected for each metabolic study for microbiome flora and&#xD;
      metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome flora</measure>
    <time_frame>4 months</time_frame>
    <description>assessed from stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiome metabolites</measure>
    <time_frame>4 months</time_frame>
    <description>assessed from stool samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT oxidative metabolism</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT triglyceride content</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined by radiodensity or MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BAT blood flow</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT net glucose uptake</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body glucose partitioning</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed using i.v. injection of 18FDG with static PET/CT scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAT volume of metabolic activity</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using a total body CT (16 mA) followed by a PET acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolites appearance rate</measure>
    <time_frame>12 months</time_frame>
    <description>will be determined by perfusion of stable isotope tracers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy metabolism (whole body production)</measure>
    <time_frame>4 months</time_frame>
    <description>by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal responses</measure>
    <time_frame>12 months</time_frame>
    <description>analysed by colorimetric and Elisa tests</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Isocaloric Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of isocaloric diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of hypercaloric diet supplemented with fructose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two weeks of hypercaloric diet supplemented with glucose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>A 2 weeks of hypercaloric diet supplemented with fructose or glucose</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cold exposure</intervention_name>
    <description>Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18FDG</intervention_name>
    <description>I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>11C-acetate</intervention_name>
    <description>i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[3-3H]-glucose</intervention_name>
    <description>i.v. administration of 1.5 uCi/min of [3-3H]-glucose</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[U-13C]-palmitate</intervention_name>
    <description>i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2H-Glycerol</intervention_name>
    <description>i.v. administration of 0.05 µmol/kg/min of 2H-glycerol</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI/MRS</intervention_name>
    <description>Visceral and cervico-thoracic MRI and MRS acquisition.</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electromyogram (EMG)</intervention_name>
    <description>Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DXA</intervention_name>
    <description>Lean mass will be determined by dual-energy X-ray absorptiometry</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.</description>
    <arm_group_label>Fructose diet</arm_group_label>
    <arm_group_label>Glucose diet</arm_group_label>
    <arm_group_label>Isocaloric Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects: subjects with normal glucose tolerance determined according to an&#xD;
             oral glucose tolerance test and with a BMI &lt; 27 kg/m2 without first degree of familial&#xD;
             history of type 2 diabetes (parents, siblings).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Plasma triglycerides &gt; 5.0 mmol/L at fasting;&#xD;
&#xD;
          2. More than 2 alcohol consumption per day;&#xD;
&#xD;
          3. More than 1 cigarette per day;&#xD;
&#xD;
          4. History of total cholesterol level &gt; 7 mmol/L, of cardiovascular disease, hypertensive&#xD;
             crisis;&#xD;
&#xD;
          5. Treatment with fibrates, thiazolidinedione, insulin, beta-blockers or other drugs with&#xD;
             effects on insulin resistance or lipid metabolism (exception for anti-hypertensive&#xD;
             drugs, statins or metformin);&#xD;
&#xD;
          6. Presence of a non-controlled thyroid disease, renal or hepatic disease, history of&#xD;
             pancreatitis, bleeding diatheses, cardiovascular disease or any other serious medical&#xD;
             conditions;&#xD;
&#xD;
          7. History of serious gastrointestinal disorders (malabsorption, peptic ulcer,&#xD;
             gastroesophageal reflux having required a surgery, etc.);&#xD;
&#xD;
          8. Presence of a pacemaker;&#xD;
&#xD;
          9. Have undergone of PET study or CT scan in the past year;&#xD;
&#xD;
         10. Chronic administration of any medication;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André C. Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

